A summary of IPOs from companies in the biotech and pharma world since April 1, 2019.
April 2019 IPO Filings and Pricings, Updated 4/30/19
Know of an IPO since April 1, 2019 that we missed? Email us at news@biospace.com.
Related: Check out BioSpace’s January list, February list, and March list.
| Date | Company Name | Amount (USD) | Company HQ | Research Focus |
|---|---|---|---|---|
| 4/29/19 | Codiak BioSciences | $86.25M Filed | Seattle, WA | Exosome therapeutics in I/O and infectious diseases |
| 4/26/19 | Peloton Therapeutics | $115M Filed | Dallas, TX | Modulating HIF-2-alpha to treat cancer and other diseases |
| 4/26/19 | Bicycle Therapeutics | $86.25M Filed | Cambridge, UK | Bicycle technology against multiple oncology targets |
| 4/26/19 | IDEAYA Biosciences | $70M Filed | South San Francisco, CA | Precision medicine targeting oncogenetic pathways and synthetic lethality |
| 4/26/19 | Karuna Pharmaceuticals | Undisclosed Filing | Boston, MA | Muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment in CNS disorders |
| 4/17/19 | Hookipa | $84M Priced | New York City, NY | Immunotherapeutics for infectious diseases and cancers using arenavirus platform |
| 4/17/19 | Brainsway | $27.5M Priced | Jerusalem, Israel | Deep TMS technology for the treatment of MDD and OCD |
| 4/17/19 | Turning Point Therapeutics | $166.5M Priced | San Diego, CA | Small molecule, targeted oncology therapies to address key limitations of existing therapies |
| 4/12/19 | NextCure | $86.25M Filed | Beltsville, MD | Immunomedicines to treat cancer and other immune-related diseases |
| 4/12/19 | Cortexyme | $86.25M Filed | South San Francisco, CA | Novel treatments for altering the course of neurodegenerative diseases |
| 4/12/19 | Applied Therapeutics | $86.25M Filed | New York City, NY | Cutting-edge technology to validated drug targets in areas of high unmet medical need |
| 4/12/19 | Milestone Pharmaceuticals | $86.25M Filed | Montreal, Quebec, Canada | Developing and commercializing etripamil for the treatment of cardiovascular indications |
| 4/5/19 | TransMedics | $86.25M Filed | Andover, MA | Organ transplant therapy for end-stage organ failure patients across multiple disease states |
| 4/5/19 | Trevi Therapeutics | $86.25M Filed | New Haven, CT | Nalbuphine ER to treat serious neurologically mediated conditions |
| 4/5/19 | Guardion Health Sciences, Inc. | $6M Priced | San Diego, CA | Targeted ocular nutrition and diagnostic technology for eye diseases |
| 4/4/19 | Silk Road Medical | $120M Priced | Sunnyvale, CA | Medical devices to improve the treatment of carotid artery disease |
| 4/4/19 | NGM Biopharmaceuticals | $106.7M Priced | South San Francisco, CA | Transformative therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases |
